Natera vs BeOne Medicines
Natera (NTRA), health care, and BeOne Medicines (ONC), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BeOne Medicines is worth $47.2B on the stock market and Natera $41.7B: BeOne Medicines is valued at 13% more. Natera's operating margin in its latest fiscal year was -13.4% and BeOne Medicines's 8.37%. Over the past year Natera's share price has moved +35.0% and BeOne Medicines's +13.0%.
Key facts
- Natera market value
- $41.7B
- BeOne Medicines market value
- $47.2B
- BeOne Medicines P/E
- 53.0
- Natera revenue
- $2.3BFY to 2025-12-31
- BeOne Medicines revenue
- $5.3BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Natera | BeOne Medicines |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $41.7Blower | $47.2Bhigher |
| Revenue | $2.3Blower | $5.3Bhigher |
| Earnings | -$208.2Mlower | $286.9Mhigher |
| Employees | 6,135lower | 12,000higher |
| Total assets | $2.4Blower | $8.2Bhigher |
| Valuation | ||
| P/E | — | 53.0 |
| P/S | 18.1higher | 8.8lower |
| P/B | 22.2 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | -13.4%lower | 8.37%higher |
| Balance sheet | ||
| Net assets | $1.7Blower | $4.4Bhigher |
| Total liabilities | $685.9Mlower | $3.8Bhigher |
| Total debt | — | $1B |
| Cash on hand | $1.1Blower | $4.5Bhigher |
| Price change | ||
| Today | -0.35%lower | +0.48%higher |
| 1 year | +35.0%higher | +13.0%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Temasek<0.1% / 0.2%
Natera only (11)
- Stanley Druckenmiller19.9%
- Andrew Spokes5.6%
- Lee Ainslie3.3%
- Philippe Laffont1.8%
- Cathie Wood1.3%
- Zach Schreiber1.2%
- Andreas Halvorsen0.3%
- Gavin Baker0.3%
- Cliff Asness0.2%
- David Shaw (founder)0.2%
- Paul Tudor Jones0.2%
BeOne Medicines only (5)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Natera / BeOne Medicines). Who owns NTRA · Who owns ONC
More on Natera
Further comparisons
Natera against its closest peers
BeOne Medicines against its closest peers
Learn
Questions and answers
Which is bigger, Natera or BeOne Medicines?
By market value, BeOne Medicines is the larger: $47.2B against $41.7B for Natera. By revenue in its latest fiscal year, BeOne Medicines is the larger: $5.3B against $2.3B for Natera.
Which has the higher operating margin?
BeOne Medicines: 8.37%, against -13.4% for Natera. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Natera and BeOne Medicines?
In their latest 13F filings, Temasek holds both.
Cite this page
Funkfolio, “Natera vs BeOne Medicines”, data as of 18 November 2026. https://funkfolio.com/compare/ntra-vs-onc
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.